Michael W. Dunne

5.5k total citations · 1 hit paper
89 papers, 3.7k citations indexed

About

Michael W. Dunne is a scholar working on Infectious Diseases, Epidemiology and Pharmacology. According to data from OpenAlex, Michael W. Dunne has authored 89 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Infectious Diseases, 33 papers in Epidemiology and 24 papers in Pharmacology. Recurrent topics in Michael W. Dunne's work include Antibiotics Pharmacokinetics and Efficacy (23 papers), Antimicrobial Resistance in Staphylococcus (21 papers) and Urinary Tract Infections Management (14 papers). Michael W. Dunne is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (23 papers), Antimicrobial Resistance in Staphylococcus (21 papers) and Urinary Tract Infections Management (14 papers). Michael W. Dunne collaborates with scholars based in United States, United Kingdom and New Zealand. Michael W. Dunne's co-authors include Sailaja Puttagunta, Helen W. Boucher, George H. Talbot, Anita Das, Sik Hung Ng, James Baldassarre, Mark Wilcox, Michael T. Zelasky, Marc Wilson and Steve Felstead and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Michael W. Dunne

86 papers receiving 3.5k citations

Hit Papers

Maraviroc for Previously Treated Patients with R5 HIV-1 I... 2008 2026 2014 2020 2008 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
    2008 570 citations Roy M. Gulick, Jacob Lalezari et al. New England Journal of Medicine profile →

Peers

Michael W. Dunne
Daniel J. Skiest United States
Amy Weintrob United States
Satish K. Pillai United States
Angela Chow Singapore
Nicola M. Zetola United States
Stefan Riedel United States
Vana Sypsa Greece
Antonino Di Italy
Carlos Álvarez Colombia
Josep Mallolas Spain
Daniel J. Skiest United States
Michael W. Dunne
Citations per year, relative to Michael W. Dunne Michael W. Dunne (= 1×) peers Daniel J. Skiest

Countries citing papers authored by Michael W. Dunne

Since Specialization
Citations

This map shows the geographic impact of Michael W. Dunne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael W. Dunne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael W. Dunne more than expected).

Fields of papers citing papers by Michael W. Dunne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael W. Dunne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael W. Dunne. The network helps show where Michael W. Dunne may publish in the future.

Co-authorship network of co-authors of Michael W. Dunne

This figure shows the co-authorship network connecting the top 25 collaborators of Michael W. Dunne. A scholar is included among the top collaborators of Michael W. Dunne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael W. Dunne. Michael W. Dunne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dagnew, Alemnew F., Ling Han, Kogieleum Naidoo, et al.. (2025). Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial. The Lancet HIV. 12(8). e546–e555. 2 indexed citations
2.
3.
Dunne, Michael W., Steven I. Aronin, Anita Das, et al.. (2024). A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections. Clinical Microbiology and Infection. 31(3). 396–401. 6 indexed citations
4.
5.
6.
Hsia, Judith, Alex C. Spyropoulos, Gregory Piazza, et al.. (2023). Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials. Thrombosis and Haemostasis. 124(7). 649–655. 1 indexed citations
7.
Dunne, Michael W., Sailaja Puttagunta, Steven I. Aronin, et al.. (2022). Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible Enterobacterales. Microbiology Spectrum. 10(1). e0235921–e0235921. 26 indexed citations
8.
Owens, Robert C., et al.. (2015). Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects. Clinical Drug Investigation. 35(12). 785–793. 15 indexed citations
9.
Dunne, Michael W., George H. Talbot, Helen W. Boucher, Mark H. Wilcox, & Sailaja Puttagunta. (2015). Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies. Drug Safety. 39(2). 147–157. 58 indexed citations
10.
Jones, Ronald N., David J. Farrell, Robert K. Flamm, et al.. (2015). Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagnostic Microbiology and Infectious Disease. 82(1). 73–77. 33 indexed citations
11.
Dunne, Michael W., et al.. (2013). Lipid targets in clinical practice: successes, failures and lessons to be learned. Irish Journal of Medical Science (1971 -). 182(4). 673–678. 4 indexed citations
12.
Gulick, Roy M., Jacob Lalezari, James Goodrich, et al.. (2008). Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. New England Journal of Medicine. 359(14). 1429–1441. 570 indexed citations breakdown →
13.
Girard, D, Steven M. Finegan, Michael W. Dunne, & Mary E. Lame. (2005). Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. Journal of Antimicrobial Chemotherapy. 56(2). 365–371. 57 indexed citations
14.
Dunne, Michael W., et al.. (2002). Thomas Aquinas, Approaches to truth : the Aquinas lectures at maynooth, 1996-2001. 4 indexed citations
15.
Haldane, John, James McEvoy, Michael W. Dunne, et al.. (2002). Mind, Metaphysics and Value in the Thomistic and Analytical Traditions. The Philosophical Quarterly. 54(216). 7 indexed citations
16.
Soto, Jaime, Julia Toledo, P. Gutiérrez, et al.. (2001). Plasmodium vivax clinically resistant to chloroquine in Colombia.. American Journal of Tropical Medicine and Hygiene. 65(2). 90–93. 107 indexed citations
17.
Dunne, Michael W.. (2000). The evolving relationship between Chlamydia pneumoniae and atherosclerosis. Current Opinion in Infectious Diseases. 13(6). 583–591. 3 indexed citations
18.
Havlir, Diane V., Michael P. Dubé, J. Allen McCutchan, et al.. (1998). Prophylaxis with Weekly Versus Daily Fluconazole for Fungal Infections in Patients with AIDS. Clinical Infectious Diseases. 27(6). 1369–1375. 49 indexed citations
19.
Havlir, Diane V., Richard Haubrich, Jimmy Hwang, et al.. (1998). Human Immunodeficiency Virus Replication in AIDS Patients withMycobacterium aviumComplex Bacteremia: A Case Control Study. The Journal of Infectious Diseases. 177(3). 595–599. 9 indexed citations
20.
Oldfield, Edward C., W. Jeffrey Fessel, Michael W. Dunne, et al.. (1998). Once Weekly Azithromycin Therapy for Prevention ofMycobacterium aviumComplex Infection in Patients with AIDS: A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Trial. Clinical Infectious Diseases. 26(3). 611–619. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel J. Skiest Breakdown of academic impact, for papers by Amy Weintrob Breakdown of academic impact, for papers by Satish K. Pillai Breakdown of academic impact, for papers by Angela Chow Breakdown of academic impact, for papers by Nicola M. Zetola Breakdown of academic impact, for papers by Stefan Riedel Breakdown of academic impact, for papers by Vana Sypsa Breakdown of academic impact, for papers by Antonino Di Breakdown of academic impact, for papers by Carlos Álvarez Breakdown of academic impact, for papers by Josep Mallolas
Rankless by CCL
2026